Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies

NCT06562543 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06562543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06562543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Recruiting
Start date
January 14, 2025
Completion date
October 4, 2027
Enrollment
78 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer